Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT ID: NCT03412877

This clinical trial is studying a new treatment for people with certain types of metastatic cancer, meaning the cancer has spread to other parts of the body and has not responded to standard therap...

Recruiting

Phase: PHASE2 Type: interventional Locations: Bethesda, Maryland, United States

Collection of Tissue Samples for Cancer Research

NCT ID: NCT00900198

This clinical trial is focused on collecting tissue samples from patients with different types of cancer, including neoplasms, lymphomas, multiple myeloma, and myelodysplastic syndrome. The goal is...

Recruiting

Type: observational Locations: Baltimore, Maryland, United States, Columbus, Ohio, United States +17 more

Tissue Collection for Studies of Lymph Cancer

NCT ID: NCT01676805

This clinical trial is focused on collecting tissue samples from patients with various types of lymph-related cancers, such as Hodgkin disease, non-Hodgkin lymphoma, and multiple myeloma. The goal ...

Recruiting

Type: observational Locations: Bethesda, Maryland, United States, Kingston, Jamaica

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT ID: NCT02682667

This clinical trial is focused on understanding different types of cancer, including multiple myeloma, lymphoma, and non-small cell lung cancer. Researchers aim to collect and study tissue and bloo...

Recruiting

Type: observational Locations: Bethesda, Maryland, United States, Bethesda, Maryland, United States

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT ID: NCT06103838

This clinical trial is studying a new imaging method using a substance called 18F-fluciclovine to see if it can better detect multiple myeloma (MM), a type of blood cancer, compared to the current ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Bethesda, Maryland, United States

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

NCT ID: NCT06876142

This clinical trial is looking at a new treatment for adults with relapsed or refractory multiple myeloma (RRMM), a type of blood cancer that often comes back after treatment or doesn’t respond to ...

Recruiting

Phase: PHASE1 Type: interventional Locations: Bethesda, Maryland, United States

National Cancer Institute "Cancer Moonshot Biobank"

NCT ID: NCT04314401

The "Cancer Moonshot Biobank" is a clinical trial that aims to gather blood and tissue samples from patients diagnosed with various types of cancer, including advanced stages of breast cancer, lung...

Recruiting

Type: observational Locations: Des Moines, Iowa, United States, Scarborough, Maine, United States +181 more

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT ID: NCT05020236

The MagnetisMM-5 clinical trial is studying a new treatment option for people with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers want to see if a medication called el...

Recruiting

Phase: PHASE3 Type: interventional Locations: Edmonton, Alberta, Canada, Dallas, Texas, United States +347 more

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT ID: NCT05317416

This clinical trial is studying a new treatment called elranatamab to see if it is more effective than a standard treatment called lenalidomide for patients with newly diagnosed multiple myeloma wh...

Recruiting

Phase: PHASE3 Type: interventional Locations: Ann Arbor, Michigan, United States, Saint John, New Brunswick, Canada +317 more

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

NCT ID: NCT05675449

This clinical trial is looking into the safety and tolerability of a new treatment for multiple myeloma, a type of blood cancer. The study is testing a combination of medicines, including elranatam...

Recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States, Iowa City, Iowa, United States +37 more

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT ID: NCT06057402

This clinical trial is designed for individuals with Multiple Myeloma, a type of blood cancer, who have previously participated in a related study and found benefit from a treatment called elranata...

Recruiting

Phase: PHASE4 Type: interventional Locations: Edmonton, Alberta, Canada, Taipei, Taiwan +27 more

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT ID: NCT06152575

The MagnetisMM-32 clinical trial is studying a new medicine called elranatamab for people with multiple myeloma (MM), a type of blood cancer that has returned after previous treatments. The trial a...

Recruiting

Phase: PHASE3 Type: interventional Locations: Boston, Massachusetts, United States, Edmonton, Alberta, Canada +274 more

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT ID: NCT06169215

This clinical trial is studying a new treatment approach for patients with high-risk newly diagnosed multiple myeloma, a type of blood cancer. Researchers are comparing a combination of four medica...

Recruiting

Phase: PHASE2 Type: interventional Locations: New Haven, Connecticut, United States, Orange, California, United States +27 more

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT ID: NCT06179888

This clinical trial is studying the effects of a medication called iberdomide in patients with multiple myeloma who have recently received a treatment called idecabtagene vicleucel, which is a type...

Recruiting

Phase: PHASE2 Type: interventional Locations: Saint Louis, Missouri, United States, Oklahoma City, Oklahoma, United States +72 more

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

NCT ID: NCT06892522

This clinical trial is designed to evaluate a new treatment called Etentamig (ABBV-383) for adults with multiple myeloma, a type of cancer affecting the blood's plasma cells. The study aims to dete...

Recruiting

Phase: PHASE1 Type: interventional Locations: Ramat Gan, Tel Aviv, Israel, Haifa, Israel +6 more

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT ID: NCT06158841

This clinical trial is studying a new treatment called ABBV-383 for adults with relapsed or refractory multiple myeloma, which is a type of blood cancer that affects plasma cells. The trial will co...

Recruiting

Phase: PHASE3 Type: interventional Locations: Ramat Gan, Tel Aviv, Israel, Tel Aviv, Tel Aviv, Israel +180 more

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT ID: NCT06953960

This clinical trial is studying a new medication called ABBV-453 for adults with multiple myeloma (MM), a type of cancer affecting the bone marrow. The trial aims to find out how safe ABBV-453 is a...

Recruiting

Phase: PHASE1 Type: interventional Locations: Tacoma, Washington, United States, Ramat Gan, Tel Aviv, Israel +9 more

Early Assessment of Cardiac Function After Treatment With CAR-T Cells

NCT ID: NCT06350994

This clinical trial is studying the potential effects of CAR-T cell therapy on heart function in patients with certain blood cancers, like leukemia and lymphoma. CAR-T cell therapy is a treatment t...

Recruiting

Type: observational Locations: Paris, France

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT ID: NCT07149857

This clinical trial is studying a new treatment called ciltacabtagene autoleucel (cilta-cel) for people with multiple myeloma, a type of blood cancer. The goal is to see how well this treatment wor...

Not yet recruiting

Phase: PHASE2 Type: interventional

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

NCT ID: NCT06461988

This clinical trial is studying the combination of two medications, talquetamab and lenalidomide, as a maintenance treatment for patients with multiple myeloma after they have undergone a stem cell...

Recruiting

Phase: PHASE2 Type: interventional Locations: Palo Alto, California, United States, Albuquerque, New Mexico, United States

Main Menu

Clinical Trials for Multiple Myeloma

420 Active Trials Found

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Collection of Tissue Samples for Cancer Research

Tissue Collection for Studies of Lymph Cancer

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

18F-Fluciclovine PET/CT in Multiple Myeloma

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

National Cancer Institute "Cancer Moonshot Biobank"

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Early Assessment of Cardiac Function After Treatment With CAR-T Cells

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Related Conditions